drugset / Trial / NCT04305444
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.
Timeline
- Start
- 2020-04-24
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DTRMWXHS-12 | Unknown | 200 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |